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Abstract
Patients with atopic dermatitis (AD) are commonly colonized/infected with Staphylococcus 
aureus, and this bacterium is known to worsen the dermatitis. In this issue, Brauweiler et al. 
demonstrate a newly discovered mechanism by which Th2 cytokines involved in AD augments the 
toxicity of the lytic staphylococcal protein alpha toxin. This review presents mechanisms by which 
Th2 cytokines may interact with S. aureus to the detriment of the dermatitis.
The vast majority (~90%) of individuals with active atopic dermatitis (AD) are colonized/
infected with Staphylococcus aureus, a species implicated in worsening the skin disease. 
The propensity of these patients to harbor staphylococcal bacteria is thought to be due in 
part to the inhibitory effects of Th2 cytokines (IL-4, IL-13) on antimicrobial peptide 
production. Through this mechanism and the inhibitory effects of these cytokines on barrier 
formation, Th2 cytokines provide an environment conducive to bacterial growth.
Given their clinical importance in the management of AD, the mechanisms by which 
staphylococcal bacteria worsen AD are areas of active study. Staphylococcal bacteria trigger 
inflammation from direct infection of cell types such as keratinocytes. Staphylococcal 
products can also exert profound effects via binding to specific receptors. With examples 
listed in Table I, these agents include exotoxins that act as superantigens, staphylococcal 
protein A, the cell wall product lipoteichoic acid, and cytolytic toxins such as staphylococcal 
alpha toxin and delta toxin. The exact importance of these staphylococcal products in AD 
associated with infection is, as yet, unknown.
Superantigens including Toxic Shock Syndrome Toxin-1 (TSST-1) and Staphylococcal 
enterotoxin B (SEB) have significant pro-inflammatory effects via their abilities to bind to 
MHCII molecules and activate large numbers of T cells. Relevant to AD, many patients 
harbor specific IgE antibodies that recognize these large globular proteins (Leung et al., 
1993). Thus, superantigen-producing S. aureus could generate type I allergic responses via 
this mechanism. Staphylococcal Protein A (SPA), a surface protein, acts as an important, yet 
complex, virulence factor contributing to the success of this pathogen by interfering with 
immune clearance and by modulating inflammation in part via its ability to activate the TNF 
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receptor 1 (TNFR1) directly. Although this would be expected to engender a pro-
inflammatory response, recent studies have suggested that through triggering of TNFR1 
shedding, SPA can actually exert anti-inflammatory effects by the removal of local TNF-α 
(Giai et al., 2013). The cell wall component lipoteichoic acid (LTA) has also been 
implicated in AD inflammation. Recent studies indicate that large (microgram) amounts of 
this toll-like receptor 2- and Platelet-activating factor receptor agonist are found on the skin 
of children with secondarily infected AD (Travers et al., 2010).
Staphylococcal bacteria also commonly express at least four cytolytic toxins that appear to 
play important roles in virulence as well as in host damage/inflammation. For example, 
recent studies have determined that delta toxin is a potent inducer of mast cell degranulation 
(Nakamura et al., 2013). Although IgE is not necessary for delta toxin-mediated mast cell 
degranulation, the presence of this allergy-associated antibody on mast cell results in 
exaggerated toxin responses (Nakamura et al., 2013). Thus, AD patients with high levels of 
IgE in response to Th2 cytokine overactivity would be especially susceptible to delta toxin-
mediated effects.
Staphylococcal alpha toxin is one of the most prominent and destructive cytolytic toxins. 
This pore-forming toxin can act on cell membranes directly, and this process appears to be 
facilitated via binding to membrane sphingomyelin molecules. Alpha toxin treatment of 
keratinocytes induces cytokine production as well as inducing cellular death (Ezepchuk et 
al., 1996; Travers et al., 2003). As reported in this issue, Brauweiler and colleagues provide 
evidence that Th2 cytokine exposure can increase the sensitivity of keratinocytes to alpha 
toxin-mediated cell death (Brauweiler et al., 2014). Alpha toxin treatment of skin biopsies 
derived from AD patients resulted in increased levels of cell death in comparison with 
normal skin. The role of Th2 cytokines was then confirmed using keratinocyte primary 
cultures treated with IL-4/IL-13. In contrast, gamma-interferon treatment did not modulate 
alpha toxin-mediated cytotoxicity. IL-4/IL-13 augmentation of alpha toxin-mediated 
cytotoxicity was shown to be due to the ability of these Th2 cytokines to decrease levels of 
acid sphingomyelinase, the enzyme that cleaves sphingomyelin into ceramide and 
phosphocholine. The ability of exogenous sphingomyelinase or phosphocholine to reverse 
the alpha toxin toxicity not only confirmed the mechanisms, but, also provided the rationale 
for possible therapeutics.
The authors also demonstrated in a recent companion report that the epidermal barrier 
protein filaggrin also plays an important role in the regulation of acid sphingomyelinase, and 
that deficiency inf filaggrin predisposes for increased alpha toxin-mediated cytotoxicity 
(Brauweiler et al., 2013). Relevant to Th2 cytokines, IL-4 and IL-13 have also been shown 
to inhibit filaggrin expression (Howell et al., 2009). Thus, one can envision a positive 
feedback pathway by which Th2 cytokines not only provide a permissive environment for S. 
aureus, but, also enhance the effects of staphylococcal products. These findings are 
compatible with the notion that strategies that remove bacteria such as dilute bleach baths 
can improve AD skin disease (Huang et al., 2009).
In summary, the interplay between Th2 cytokines and S. aureus has high significance for 
understanding AD. Indeed, the majority of AD flares involve S. aureus in some capacity. 
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New insights into the exact mechanisms by which staphylococcal exposure can worsen AD 
could allow improved and novel treatments for this common skin disease and its significant 
morbidities.
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Clinical Implications
Staphylococcal infection is a known trigger for worsening of atopic dermatitis skin 
disease, likely through multiple mechanisms.
These studies describe a novel mechanism by which Th2 cytokines associated with 
atopic dermatitis patients can worsen the effects of alpha toxin, a major cytotoxic 
protein produced by Staphylococcus aureus.
The ability to block the effects of alpha toxin via use of exogenous acid 
sphingomyelinase or phosphocholine provides the impetus for novel therapeutics to 
treat atopic dermatitis patients with chronic skin staphylococcal infections.
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Table I
Mechanisms by which staphylococcal products can modulate AD and role of Th2 cytokines.
Staphylococcal Mediator Effect on AD Skin Lesion Th2 cytokine effect References
Alpha toxin Increased keratinocyte cell death and worsening 
of lesion; increased cytokine production
Increased toxicity via 
inhibiting filaggrin, acid 
sphingomyelinase
Brauweiler et al., 
2013, 2014
Delta toxin Increased mast cell degranulation and 
worsening of lesion
Increased effect via increased 
IgE production
Nakamura et al., 
2013
Superantigen (SEB, TSST-1…) Increased mast cell degranulation and release of 
cytokines via triggering specific IgE molecules 
and worsening of lesion
Increased effect via increased 
IgE production
Leung et al., 1993
Staphylococcal Protein A Unclear effects; Increased inflammation via 
signaling through TNFR1 versus anti-
inflammatory effects via removal of TNF-α
Not known Giai et al., 2013
Lipoteichoic acid Increased inflammation via signaling through 
TLR2 and Platelet-activating factor receptor and 
worsening of lesion
Not known Travers et al., 2010
J Invest Dermatol. Author manuscript; available in PMC 2015 February 01.
